Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years
Ann Rheum Dis. 2021. Epub ahead of print. doi: 10.1136/annrheumdis-2021-221051
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Ann Rheum Dis. 2021. Epub ahead of print. doi: 10.1136/annrheumdis-2021-221051
J Rheumatol. 2021 Feb 1:jrheum.201183. DOI: 10.3899/jrheum.201183.
PLoS ONE 2021;16(1):e0244187
Ann Rheum Dis. 2021 Jan 27:annrheumdis-2020-219214
Please click the links below to go to the CSF review of each paper
Annals of the Rheumatic Diseases, May 2020
Lancet Rheumatol 2020;2:e347–57
Arthritis Rheumatol. 2020 Sep; 72(9): 1435–1446.
RMD Open 2020;6:e001095
Please click the links below to go to the CSF review of each paper